Atrial Fibrillation History Feature vs Zio XT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by iRhythm Technologies

AI Verdict

Tool A (Apple's AFib History Feature) is designed for diagnosed AFib patients to retrospectively track AFib burden and understand lifestyle influences, providing data for physician review. In contrast, Tool B (Zio XT ECG Monitoring System) is a diagnostic tool offering up to 14 days of continuous ECG monitoring to detect and diagnose various arrhythmias. While both utilize wearables and AI for cardiac health, Tool A focuses on ongoing management for diagnosed individuals, whereas Tool B is geared towards initial detection and diagnosis.

Choose Atrial Fibrillation History Feature if…

Choose the Atrial Fibrillation History Feature if you are a diagnosed AFib patient seeking to understand the long-term trends of your condition and how lifestyle factors influence it. This tool is ideal for personal insight and generating retrospective data summaries to discuss with your physician during routine follow-ups.

View Atrial Fibrillation History Feature →

Choose Zio XT ECG Monitoring System if…

Choose the Zio XT ECG Monitoring System if a healthcare provider needs a comprehensive, diagnostic-grade continuous ECG recording for up to 14 days to detect and accurately diagnose suspected arrhythmias. This system is designed for clinical investigation, offering expert-reviewed data and HIPAA compliance for a precise diagnostic workup.

View Zio XT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Atrial Fibrillation History Feature Zio XT ECG Monitoring System
Pricing Unknown Contact for pricing
Deployment Mobile App Cloud-based (AWS EC2 platform), no on-premise hardware required.
BAA Available No AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA No AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Atrial Fibrillation History Feature

Tool A integrates seamlessly into a widely adopted consumer device ecosystem (Apple Watch and iPhone), offering passive, continuous insights for diagnosed users without requiring a separate device or significant behavioral change beyond wearing their watch. This makes its ongoing usability for long-term tracking exceptionally high for those already within the Apple ecosystem.

Clinical Value

Zio XT ECG Monitoring System

Tool B offers direct diagnostic capabilities through continuous ECG monitoring for up to 14 days, utilizing FDA-cleared AI and expert review to detect and diagnose arrhythmias. This provides critical, actionable data for initial diagnosis and treatment planning, whereas Tool A focuses on retrospective insights for already diagnosed individuals and is not intended for real-time detection or continuous monitoring.

Pricing & Value

Atrial Fibrillation History Feature

Tool A's AFib History feature is included as part of the Apple Watch purchase, incurring no additional cost for users who already own a compatible device. In contrast, Tool B is a dedicated medical service with a distinct per-patient cost (e.g., u00a3310 in the UK, ~$229-$260 in the US for Medicare), making Tool A a more cost-effective option for ongoing insights for existing Apple Watch users.

Enterprise Readiness

Zio XT ECG Monitoring System

Tool B explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), along with a cloud-based deployment on AWS EC2 and a dedicated software platform for data management. This demonstrates a clear design for secure and compliant integration within healthcare enterprises, which Tool A lacks with its consumer-focused deployment and explicit 'no' for BAA/HIPAA compliance.

Innovation

Zio XT ECG Monitoring System

Tool B showcases significant innovation in dedicated medical device technology with its comfortable, wire-free biosensor for extended continuous ECG monitoring and its proprietary, FDA-cleared deep-learned AI algorithm for accurate arrhythmia detection and diagnosis. While Tool A innovates by integrating FDA-cleared health features into a mass-market consumer device, Tool B's advancements are more focused on core medical diagnostic technology and patient experience for a specialized purpose.

Support & Docs

Tie

Both Apple and iRhythm Technologies provide comprehensive support and documentation tailored to their respective product types and user bases. Apple offers extensive online resources and customer support for its consumer devices, while iRhythm provides detailed clinical manuals, patient instructions, and dedicated customer care for its medical device.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Atrial Fibrillation History Feature Zio XT ECG Monitoring System
Name Atrial Fibrillation History Feature Zio XT ECG Monitoring System
Company Apple iRhythm Technologies
Description Apple's AFib History Feature on Apple Watch provides diagnosed users with retrospective estimates of AFib burden and insights into how lifestyle factors may influence their condition, with data exportable for physician review. The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Key Features Retrospective AFib burden estimation (weekly percentage), Tracking and trending AFib burden over time, Visualization of lifestyle factors (sleep, activity, alcohol, weight, mindful minutes) impacting AFib, Weekly notifications and summaries of AFib frequency, PDF export of AFib History data for sharing with healthcare providers, Requires a prior physician diagnosis of AFib for activation, Compatible with Apple Watch Series 4 or later and iPhone 8 or later, Not intended for real-time AFib detection or continuous monitoring Wearable single-lead ECG biosensor (Zio biosensor), Continuous ambulatory cardiac monitoring for up to 14 days, Water-resistant design for normal daily activities, including showering, No external leads or wires for enhanced patient comfort and reduced artifacts, Proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis, Cloud-based software platform (ZEUS) for data storage, analysis, and reporting, Patient-activated button for symptomatic event logging, High patient compliance (up to 99%) and satisfaction

Videos

Demos, reviews, and walkthroughs featuring Atrial Fibrillation History Feature and Zio XT ECG Monitoring System.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tool A, Apple's AFib History Feature, is designed for diagnosed users to retrospectively estimate AFib burden and understand lifestyle impacts. Tool B, the Zio XT ECG Monitoring System, provides continuous cardiac monitoring for up to 14 days to detect and diagnose arrhythmias.
Tool A explicitly requires a prior physician diagnosis of AFib for activation. Tool B, the Zio XT system, is indicated for use in patients who may be asymptomatic or suffer from transient symptoms, and is used for arrhythmia detection and diagnosis.
Tool B, the Zio XT ECG Monitoring System, is HIPAA compliant and has a Business Associate Agreement (BAA). Tool A, Apple's AFib History Feature, states it is not HIPAA compliant and does not have a BAA.
Tool A provides retrospective weekly percentage estimates of AFib burden and visualizations of lifestyle factors, with data exportable as a PDF. Tool B offers continuous single-lead ECG monitoring for up to 14 days, utilizing AI and expert review for arrhythmia detection and diagnosis, with data available through a cloud-based platform and detailed reports.
Tool A is explicitly stated as not being intended for real-time AFib detection or continuous monitoring. Tool B, the Zio XT system, is designed for continuous ambulatory cardiac monitoring for up to 14 days to detect cardiac arrhythmias.
Tool A allows for PDF export of AFib History data from the Health app for sharing with healthcare providers. Tool B uses a cloud-based software platform (ZEUS) for data storage, analysis, and reporting, which provides a clinically actionable summary to the prescribing healthcare professional.

Backers

Who funded each tool's parent company.

Atrial Fibrillation History Feature

AI Tool Finder
AI-powered search. Results may not be comprehensive.